secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0002023658-25-000094
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara Therapeutics Q2 2025: Cash $436.6M, net loss $27.4M; Phase 1/1b data show 54% ORR in HNSCC
--------------------------------------------------------------------------------

- Cash and equivalents $436.6M as of Jun 30, 2025, expected to fund operations into H1 2029.
- Q2 2025 net loss $27.4M vs $17.0M in Q2 2024; R&D expenses $24.8M (up $9M YoY) due to FORTIFI-HN01 trial.
- Updated Phase 1/1b data: 54% confirmed ORR, median DOR 21.7 months, median OS 21.3 months in 1L HPV-negative R/M HNSCC.
- Additional dose-cohort data (750mg weekly, 2000mg Q2W) expected Q4 2025–Q1 2026; enrollment ongoing in pivotal Phase 2/3.
- Pivotal Phase 2/3 FORTIFI-HN01 trial of ficerafusp alfa + pembrolizumab in 1L R/M HNSCC continues enrolling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/0002023658-25-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/bcax-20250812.htm
  HTML page:      https://secwatch.observer/filing/0002023658-25-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer